• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在接受程序性细胞死亡受体-1和乐伐替尼治疗的肝细胞癌真实世界队列中对纤维蛋白原客观反应的早期预测

Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib.

作者信息

Shen Yanjun, Wang Huige, Wei Jianying, Li Wendong

机构信息

Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.

Department of Gynecology, Wangjing Hospital of Chinese Academy of Chinese Medical, Beijing, 100102, People's Republic of China.

出版信息

Onco Targets Ther. 2021 Oct 7;14:5019-5026. doi: 10.2147/OTT.S332351. eCollection 2021.

DOI:10.2147/OTT.S332351
PMID:34675546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8513529/
Abstract

BACKGROUND

This cohort study aimed to investigate the influence of fibrinogen on progression-free survival and overall survival in unresectable HCC cases treated by PD-1 and lenvatinib.

METHODS

A total of 57 unresectable HCC cases who received lenvatinib and PD-1, such as toripalimab, camrelizumab, or sintilimab, in Beijing Ditan Hospital Affiliated to Capital Medical University were enrolled in this study.

RESULTS

Vascular invasion, high FIB (>2.83g/L), and metastasis were highly correlated with low PFS. There was a significant correlation between a raised risk of death and metastasis and increased FIB (>2.83g/L).

CONCLUSION

FIB is associated with outcomes of unresectable HCC cases treated by PD-1 and lenvatinib.

摘要

背景

本队列研究旨在调查纤维蛋白原对接受PD - 1和乐伐替尼治疗的不可切除肝癌患者无进展生存期和总生存期的影响。

方法

本研究纳入了首都医科大学附属北京地坛医院57例接受乐伐替尼和PD - 1（如特瑞普利单抗、卡瑞利珠单抗或信迪利单抗）治疗的不可切除肝癌患者。

结果

血管侵犯、高纤维蛋白原（>2.83g/L）和转移与低无进展生存期高度相关。死亡风险增加与转移及纤维蛋白原升高（>2.83g/L）之间存在显著相关性。

结论

纤维蛋白原与接受PD - 1和乐伐替尼治疗的不可切除肝癌患者的预后相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0a/8513529/3267eb8f0c4b/OTT-14-5019-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0a/8513529/b84e13b672a6/OTT-14-5019-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0a/8513529/3267eb8f0c4b/OTT-14-5019-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0a/8513529/b84e13b672a6/OTT-14-5019-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0a/8513529/3267eb8f0c4b/OTT-14-5019-g0002.jpg

相似文献

1
Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib.在接受程序性细胞死亡受体-1和乐伐替尼治疗的肝细胞癌真实世界队列中对纤维蛋白原客观反应的早期预测
Onco Targets Ther. 2021 Oct 7;14:5019-5026. doi: 10.2147/OTT.S332351. eCollection 2021.
2
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.托法替布、卡瑞利珠单抗和信迪利单抗在乙型肝炎病毒相关肝细胞癌患者真实世界队列中的有效性和安全性。
Ann Transl Med. 2020 Sep;8(18):1187. doi: 10.21037/atm-20-6063.
3
Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.乐伐替尼联合PD-1阻断剂治疗晚期肝细胞癌的真实世界疗效：拓展适应症探索
BMC Cancer. 2022 Mar 19;22(1):293. doi: 10.1186/s12885-022-09405-7.
4
Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients.抗程序性死亡蛋白1（PD-1）抗体联合乐伐替尼用于乐伐替尼治疗后疾病进展的不可切除肝细胞癌患者：一项真实世界患者的回顾性队列研究
J Gastrointest Oncol. 2022 Aug;13(4):1898-1906. doi: 10.21037/jgo-22-643.
5
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.乐伐替尼与索拉非尼作为不可切除肝细胞癌经动脉治疗挽救疗法的真实世界比较分析
J Clin Med. 2020 Dec 21;9(12):4121. doi: 10.3390/jcm9124121.
6
Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.特瑞普利单抗联合肝动脉灌注化疗与仑伐替尼治疗晚期肝细胞癌的比较
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211063848. doi: 10.1177/15330338211063848.
7
Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.乐伐替尼联合卡瑞利珠单抗与乐伐替尼单药作为晚期肝细胞癌进展后治疗的短期预后研究
Cancer Manag Res. 2021 May 27;13:4233-4240. doi: 10.2147/CMAR.S304820. eCollection 2021.
8
Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study.不同PD-1抑制剂联合乐伐替尼治疗不可切除原发性肝癌的疗效与安全性：一项多中心回顾性研究
Discov Oncol. 2023 Jun 19;14(1):105. doi: 10.1007/s12672-023-00708-0.
9
A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China.在中国进行的关于乐伐替尼单药治疗或联合程序性细胞死亡蛋白1抗体治疗肝细胞癌或肝内胆管癌患者的回顾性研究。
Front Oncol. 2021 Dec 17;11:788635. doi: 10.3389/fonc.2021.788635. eCollection 2021.
10
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.仑伐替尼单药治疗美国不可切除肝细胞癌患者的真实世界疗效。
Future Oncol. 2021 Jul;17(21):2759-2768. doi: 10.2217/fon-2021-0242. Epub 2021 Apr 9.

引用本文的文献

1
The delaying effect of toripalimab on disease progression in patients with advanced hepatocellular carcinoma and changes in serum tumor markers.托法替布对晚期肝细胞癌患者疾病进展的延缓作用及血清肿瘤标志物的变化
World J Surg Oncol. 2025 Jul 1;23(1):254. doi: 10.1186/s12957-025-03884-1.
2
The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.乙肝病毒载量会降低免疫检查点抑制剂对肝细胞癌患者的疗效。
Front Immunol. 2024 Nov 27;15:1480520. doi: 10.3389/fimmu.2024.1480520. eCollection 2024.
3
Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.

本文引用的文献

1
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR.PD-L1 招募磷脂酶 C 并增强携带 EGFR 突变的肺肿瘤的致瘤性。
Cell Rep. 2021 May 25;35(8):109181. doi: 10.1016/j.celrep.2021.109181.
2
A preoperative risk prediction model for high malignancy potential gastrointestinal stromal tumors of the stomach.术前预测胃高恶性潜能胃肠道间质瘤风险的模型。
Surg Endosc. 2022 Mar;36(3):2129-2137. doi: 10.1007/s00464-021-08501-2. Epub 2021 May 17.
3
A nomogram combining plasma fibrinogen and systemic immune‑inflammation index predicts survival in patients with resectable gastric cancer.
基于对 47 个队列的系统评价和荟萃分析，开发和验证了免疫检查点抑制剂治疗肝细胞癌患者的预后风险预测模型。
Front Immunol. 2023 Jul 14;14:1215745. doi: 10.3389/fimmu.2023.1215745. eCollection 2023.
4
Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment.使用免疫疗法作为二线治疗的癌症患者，治疗前的纤维蛋白原水平与生存结果相关。
Oncol Lett. 2023 May 5;25(6):269. doi: 10.3892/ol.2023.13855. eCollection 2023 Jun.
5
Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.免疫检查点抑制剂治疗合并大血管侵犯或肝外转移的肝细胞癌患者的疗效和安全性：54 项研究 6187 例肝细胞癌患者的系统评价和荟萃分析。
Cancer Immunol Immunother. 2023 Jul;72(7):1957-1969. doi: 10.1007/s00262-023-03390-x. Epub 2023 Feb 22.
联合血浆纤维蛋白原和全身免疫炎症指数的列线图预测可切除胃癌患者的生存情况。
Sci Rep. 2021 May 13;11(1):10301. doi: 10.1038/s41598-021-89648-9.
4
Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients.血浆纤维蛋白原可作为乳腺癌新辅助化疗病理完全缓解的预测因素：1004 例中国乳腺癌患者的回顾性研究。
BMC Cancer. 2021 May 12;21(1):542. doi: 10.1186/s12885-021-08284-8.
5
Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy.肿瘤微环境中的纤溶酶和纤溶酶原系统：对癌症诊断、预后及治疗的意义
Cancers (Basel). 2021 Apr 12;13(8):1838. doi: 10.3390/cancers13081838.
6
The preoperative elevated plasma fibrinogen level is associated with the prognosis of hilar cholangiocarcinoma.术前血浆纤维蛋白原水平升高与肝门部胆管癌的预后相关。
Surg Today. 2021 Aug;51(8):1352-1360. doi: 10.1007/s00595-021-02249-x. Epub 2021 Mar 2.
7
Prognostic role of preoperative D-dimer, fibrinogen and platelet levels in patients with oral squamous cell carcinoma.术前D-二聚体、纤维蛋白原和血小板水平在口腔鳞状细胞癌患者中的预后作用。
BMC Cancer. 2021 Feb 5;21(1):122. doi: 10.1186/s12885-021-07841-5.
8
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.托法替布、卡瑞利珠单抗和信迪利单抗在乙型肝炎病毒相关肝细胞癌患者真实世界队列中的有效性和安全性。
Ann Transl Med. 2020 Sep;8(18):1187. doi: 10.21037/atm-20-6063.
9
Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival.射频消融后肝细胞癌的晚期复发：多中心危险因素、模式和生存研究。
Eur Radiol. 2021 May;31(5):3053-3064. doi: 10.1007/s00330-020-07460-x. Epub 2020 Nov 11.
10
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.